vimarsana.com

Latest Breaking News On - Therapeutics company profile - Page 28 : vimarsana.com

McGuire Investment Group LLC Sells 809 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

McGuire Investment Group LLC lowered its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 58,597 shares of the company’s stock after selling 809 shares during the quarter. McGuire […]

Schroder Investment Management Group Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Schroder Investment Management Group trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 125,013 shares of the company’s stock after selling 1,768 shares during the quarter. Schroder Investment Management Group owned […]

IMA Wealth Inc Sells 255 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

IMA Wealth Inc. cut its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,517 shares of the company’s stock after selling 255 shares during the period. IMA Wealth Inc.’s […]

PTC Therapeutics, Inc (NASDAQ:PTCT) Receives Average Recommendation of Reduce from Brokerages

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus recommendation of “Reduce” from the fifteen brokerages that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and three have issued a buy recommendation on the company. […]

PTC Therapeutics, Inc (NASDAQ:PTCT) Receives $34 40 Average PT from Analysts

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has received a consensus recommendation of “Reduce” from the fifteen ratings firms that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have assigned a buy recommendation to the […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.